Longeveron (LGVN) Operating Income Growth (1y) (2021 - 2026)
Longeveron (LGVN) Operating Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 183.45% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 7.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.84% |
| Dec 31, 2025 | -26.12% |
| Sep 30, 2025 | -57.24% |
| Jun 30, 2025 | -54.20% |
| Mar 31, 2025 | -26.67% |
| Dec 31, 2024 | 21.31% |
| Sep 30, 2024 | 9.92% |
| Jun 30, 2024 | 38.73% |
| Mar 31, 2024 | 13.27% |
| Dec 31, 2023 | -3.80% |
| Sep 30, 2023 | 0.50% |
| Jun 30, 2023 | -35.32% |
| Mar 31, 2023 | -38.95% |
| Dec 31, 2022 | -29.99% |
| Sep 30, 2022 | -5.75% |
| Jun 30, 2022 | 16.61% |
| Mar 31, 2022 | 1.85% |
| Dec 31, 2021 | -191.54% |
| Sep 30, 2021 | -412.00% |
| Jun 30, 2021 | -312.89% |